NBIX vs NHI · P/E 45, rev $1.77B vs P/E 22, rev $54.4M
Neurocrine Biosciences Inc (NBIX) versus National Health Investors Inc (NHI) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
National Health Investors Inc (NHI) is a reit - healthcare facilities company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported NHI revenue for 2024-12-31 was $54.4M. Net income was $136.6M. Revenue was up 11.5% from 2023-12-31 to 2024-12-31. NHI currently screens at market cap $3.31B and trailing P/E 22.4.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NHI currently screens at market cap $3.31B and trailing P/E 22.4.
Not investment advice. Open the NBIX and NHI stock pages for the full models.
Not investment advice.